20.38
0.53 (2.67%)
| Previous Close | 19.85 |
| Open | 19.82 |
| Volume | 675,731 |
| Avg. Volume (3M) | 897,626 |
| Market Cap | 876,773,568 |
| Price / Earnings (TTM) | 43.36 |
| Price / Earnings (Forward) | 9.11 |
| Price / Sales | 1.37 |
| Price / Book | 1.29 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -14.76% |
| Operating Margin (TTM) | 4.63% |
| Diluted EPS (TTM) | -2.24 |
| Quarterly Revenue Growth (YOY) | 1.10% |
| Quarterly Earnings Growth (YOY) | -46.40% |
| Total Debt/Equity (MRQ) | 79.70% |
| Current Ratio (MRQ) | 2.41 |
| Operating Cash Flow (TTM) | 175.75 M |
| Levered Free Cash Flow (TTM) | 144.75 M |
| Return on Assets (TTM) | 3.56% |
| Return on Equity (TTM) | -12.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Pacira BioSciences, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.70 |
|
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.79% |
| % Held by Institutions | 110.89% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 38.00 (HC Wainwright & Co., 86.46%) | Buy |
| Median | 34.00 (66.83%) | |
| Low | 30.00 (Needham, 47.20%) | Buy |
| Average | 34.00 (66.83%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 23.53 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Jan 2026 | 38.00 (86.46%) | Buy | 23.53 |
| Needham | 09 Jan 2026 | 30.00 (47.20%) | Buy | 23.53 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FROIMSON MARK | - | 21.94 | -500 | -10,970 |
| SLONIN JONATHAN | - | 21.94 | -3,261 | -71,546 |
| Aggregate Net Quantity | -3,761 | |||
| Aggregate Net Value ($) | -82,516 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 21.94 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FROIMSON MARK | Director | 17 Mar 2026 | Sell (-) | 500 | 21.94 | 10,970 |
| SLONIN JONATHAN | Officer | 17 Mar 2026 | Automatic sell (-) | 3,261 | 21.94 | 71,546 |
| Date | Type | Details |
|---|---|---|
| 28 Jan 2026 | Announcement | Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors |
| 13 Jan 2026 | Announcement | Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets |
| 08 Jan 2026 | Announcement | Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues |
| 07 Jan 2026 | Announcement | Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences |
| 30 Dec 2025 | Announcement | DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |